Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
CSE:ZEAL
Price:
573.5
DKK
1.06%
Market Closed
Market Cap:
40.7B
DKK
Balance Sheet
Balance Sheet Decomposition
Zealand Pharma A/S
Zealand Pharma A/S
| Current Assets | 8.5B |
| Cash & Short-Term Investments | 8.2B |
| Receivables | 291m |
| Other Current Assets | 10.7m |
| Non-Current Assets | 977.9m |
| Long-Term Investments | 819.6m |
| PP&E | 125.2m |
| Intangibles | 12.6m |
| Other Non-Current Assets | 20.4m |
Balance Sheet
Zealand Pharma A/S
Zealand Pharma A/S
Currency: DKK
Millions
Annual
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
419
|
323
|
589
|
861
|
1 081
|
960
|
1 129
|
1 069
|
449
|
480
|
|
| Cash Equivalents |
419
|
323
|
589
|
861
|
1 081
|
960
|
1 129
|
1 069
|
449
|
480
|
|
| Short-Term Investments |
0
|
0
|
75
|
299
|
299
|
297
|
299
|
109
|
1 184
|
7 746
|
|
| Total Receivables |
174
|
22
|
16
|
8
|
16
|
62
|
110
|
83
|
111
|
176
|
|
| Accounts Receivables |
158
|
12
|
6
|
3
|
1
|
46
|
73
|
1
|
1
|
0
|
|
| Other Receivables |
16
|
11
|
10
|
5
|
15
|
15
|
37
|
81
|
110
|
175
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
65
|
118
|
1
|
8
|
11
|
|
| Other Current Assets |
24
|
27
|
7
|
12
|
31
|
35
|
65
|
54
|
28
|
115
|
|
| Total Current Assets |
617
|
373
|
687
|
1 179
|
1 427
|
1 420
|
1 722
|
1 316
|
1 780
|
8 528
|
|
| PP&E Net |
16
|
14
|
16
|
16
|
125
|
213
|
221
|
165
|
150
|
125
|
|
| PP&E Gross |
16
|
14
|
16
|
16
|
125
|
213
|
221
|
165
|
150
|
125
|
|
| Accumulated Depreciation |
70
|
48
|
53
|
56
|
58
|
53
|
69
|
71
|
70
|
78
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
2
|
57
|
54
|
0
|
12
|
13
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
18
|
16
|
19
|
|
| Long-Term Investments |
0
|
0
|
9
|
33
|
36
|
32
|
27
|
38
|
21
|
820
|
|
| Other Long-Term Assets |
3
|
308
|
9
|
3
|
9
|
38
|
43
|
2
|
1
|
1
|
|
| Total Assets |
636
N/A
|
695
+9%
|
721
+4%
|
1 230
+71%
|
1 600
+30%
|
1 762
+10%
|
2 068
+17%
|
1 540
-26%
|
1 980
+29%
|
9 506
+380%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
22
|
20
|
29
|
33
|
58
|
70
|
65
|
181
|
92
|
181
|
|
| Accrued Liabilities |
25
|
30
|
32
|
35
|
36
|
101
|
85
|
0
|
85
|
167
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
3
|
3
|
0
|
8
|
14
|
15
|
15
|
17
|
16
|
|
| Other Current Liabilities |
25
|
34
|
9
|
46
|
94
|
170
|
170
|
0
|
91
|
40
|
|
| Total Current Liabilities |
71
|
88
|
74
|
114
|
195
|
355
|
334
|
195
|
285
|
403
|
|
| Long-Term Debt |
313
|
329
|
133
|
0
|
78
|
116
|
773
|
509
|
103
|
376
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
84
|
61
|
33
|
19
|
0
|
110
|
|
| Total Liabilities |
384
N/A
|
416
+8%
|
207
-50%
|
114
-45%
|
357
+214%
|
533
+49%
|
1 140
+114%
|
724
-36%
|
387
-47%
|
889
+130%
|
|
| Equity | |||||||||||
| Common Stock |
24
|
26
|
31
|
31
|
36
|
40
|
44
|
52
|
59
|
71
|
|
| Retained Earnings |
1 035
|
1 189
|
1 475
|
894
|
1 444
|
2 290
|
3 308
|
750
|
4 895
|
6 157
|
|
| Additional Paid In Capital |
1 263
|
1 441
|
1 959
|
1 979
|
2 650
|
3 471
|
4 250
|
0
|
6 406
|
14 681
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
72
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
9
|
14
|
15
|
23
|
22
|
|
| Total Equity |
252
N/A
|
278
+10%
|
515
+85%
|
1 116
+117%
|
1 243
+11%
|
1 229
-1%
|
928
-25%
|
816
-12%
|
1 593
+95%
|
8 617
+441%
|
|
| Total Liabilities & Equity |
636
N/A
|
695
+9%
|
721
+4%
|
1 230
+71%
|
1 600
+30%
|
1 762
+10%
|
2 068
+17%
|
1 540
-26%
|
1 980
+29%
|
9 506
+380%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
24
|
26
|
28
|
31
|
36
|
40
|
43
|
51
|
58
|
71
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
